Physician profile
Jeffrey Wayne Sherman
NPI 1134499593
$527,125.81
in general payments reported to CMS, 2019-2025
4 companies · $139K in 2025
The $139K reported for 2025 was more than what 99% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $111 · 2020: $23K · 2021: $79K · 2022: $72K · 2023: $55K · 2024: $159K · 2025: $139K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $221K · Honoraria: $124K · Travel and Lodging: $7,184 · Food and Beverage: $1,795.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $220,844.62 |
| Honoraria | $123,625.00 |
| Travel and Lodging | $7,184.23 |
| Food and Beverage | $1,795.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $357,263.25 | 2020-2025 | |
| Amgen INC. | $169,729.32 | 2024-2025 | Tepezza |
| Romark Laboratories, Lc | $110.70 | 2019 | |
| Alnylam Pharmaceuticals INC. | $22.54 | 2024 | Givlaari |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Sherman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.